MAP3K7 and pulmonary arterial hypertension: Based on these evidences, we hypothesized that sustained inhibition of TAK1 with the low molecular weight inhibitor 5Z-7-oxozeaenol in combination with a vasodilator therapy such as the soluble guanylate cyclase (sGC) stimulator riociguat could ameliorate or even reverse pulmonary vascular remodeling and RV dysfunction in PAH by their ability to limit inflammation and metabolic disruption and to mitigate vascular and cardiac remodeling.